Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?
Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Source: Prosper Junior Bakiny (us) · fool.com